Celebrity Inventors
Actress Jamie Lee Curtis is a patented inventor - she created a diaper equipped with a premoistened baby wipe. And that's no act!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7973185 | Process for the preparation of phenolic hydroxy-substituted compounds The invention relates to a process for the preparation of a phenolic hydroxy-substituted compound of the general formula (I) by desalkylation of an alkyl aryl ether of the general formula (II) by treatment with a thiourea/aluminum chloride reagent pair, in said gene... | 07/05/2011 |
| 7435757 | 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which R2 means a C1-C8-alkyl group, a C1-C | 10/14/2008 |
| 7378404 | 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens This invention describes the new 8β-substituted estratrienes of general formula I in which R2, R3, R6, R6′, R7, R7′, R9, R11, R11′, R12, R14 | 05/27/2008 |
| 7371741 | Estradiol derivatives and pharmaceutical compositions using same Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification. ... | 05/13/2008 |
| 7342004 | Thioether sulphamate steroids as steroid inhibitors and anti-cancer compounds There is provided use of a compound of Formula XI: wherein R3 is a sulphamate group and at least of R1 or R2 is a thioether group as disclosed by the present specification, capable of inhibi... | 03/11/2008 |
| RE39592 | Extended release growth promoting two component composition An extended release composition comprising a first composition comprising growth promoters and a second composition comprising growth promoters and a biodegradable polymer is described. A method of increasing weight gain in food animals utilizing the composition, a ... | 04/24/2007 |
| 7179799 | (3) and (6) substituted estrogenic compounds Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the... | 02/20/2007 |
| 7109360 | 16-hydroxyestratrienes as selectively active estrogens The invention describes new compounds as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action on bone rat... | 09/19/2006 |
| 6995278 | Antiangiogenic agents Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the spec... | 02/07/2006 |
| 6992075 | C(14) estrogenic compounds The present invention relates to novel estrogenic compounds. The present invention also relates to methods of treating estrogen deprivation in a subject comprising administering novel estrogenic compounds. Additionally, the present invention relates to methods of sy... | 01/31/2006 |
| 6962908 | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17β-estradiol-3-lower alkanoate, most preferably 17β-estradiol-3-acetate, and a pharmaceutically acceptable carrier is disclosed. Also disclosed... | 11/08/2005 |
| 6958327 | 18 Norsteroids as selectively active estrogens The invention relates to novel 18-norsteroids (gonatrienes) of general formula (I), wherein R1, R2, R3, R6, R7, R8, R9, R11, R11′, R14, R15, R | 10/25/2005 |
| 6831073 | Hormonal composition consisting of an oestrogen compound and of a progestational compound A method of treating estrogenic deficiencies in women while further avoiding the appearance of osteoporosis, withdrawal bleeding and cardiovascular diseases in post-menopausal women without any androgenic effect, and no deleterious effects on blood vessels comprisin... | 12/14/2004 |
| 6767903 | New7α, 17α-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases The invention relates to new 7α, 17α, 17β-substituted testosterone derivatives of general formula (I) and their use as pure antiandrogens for the long-term therapy of androgen-dependent diseases, notably for the long-term antiandrogen therapy of prostate carcinom... | 07/27/2004 |
| 6689768 | Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy The pharmaceutical preparations for treating side effects, such as hot flashes, prostate enlargement and gynecomastia, during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone (GnRHa therapy) contain an effective amount ... | 02/10/2004 |
| 6670348 | Methods and compositions for destruction of selected proteins Compounds having an ansamycin anitibiotic, or other moiety which binds to hsp90, coupled to a targeting moiety which binds specifically to a protein, receptor or marker can provide effective targeted delivery of the ansamycin antibiotic leading to the deg... | 12/30/2003 |
| 6596885 | 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions Novel compounds having a formula selected from the group consisting of ##STR1## wherein the substituents are defined as in the specification which are intermediates for the production of vinyl compounds having a remarkable anti-estrogenic and anti-prolife... | 07/22/2003 |
| 6579995 | Process for phosphorylation and compounds produced by this process The present invention is directed to improved processes for phosphorylation and compounds produced by the improved processes. The improved process for phosphorylating complex alcohols comprises the following steps: (a) forming an intimate mixture of one o... | 06/17/2003 |
| 6544971 | Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices A method of increasing alertness in an individual by administering an effective amount of an alertness-increasing vomeropherin to the individual; and an alarm device that, when activated, emits an alertness-increasing vomeropherin. The method and device a... | 04/08/2003 |
| 6498153 | Extended release growth promoting two component composition An extended release composition comprising a first composition comprising growth promoters and a second composition comprising growth promoters and a biodegradable polymer is described. A method of increasing weight gain in food animals utilizing the comp... | 12/24/2002 |
| 6476012 | Estradiol-16-carboxylic acid esters as locally active estrogens The present invention relates to analogs of estradiol, which, in their most preferred embodiment, act as locally active estrogens without significant systemic action. A series of 16-carboxylic acid substituted steroids and their esters is presented... | 11/05/2002 |
| 6462211 | 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them A subject of the invention is the compounds of formula (I): ##STR1## in which X is a halogen atom, D represents the remainder of an optionally substituted pentagonal or hexagonal ring and optionally carrying an unsaturation, R1, R2, ... | 10/08/2002 |
| 6436917 | Non-estrogenic estradiol derivative compounds with anti-oxidative activity New non-estrogenic derivative compounds of estradiol, which have no estrogenic activity and comparatively high anti-oxidative activity, are disclosed. These new non-estrogenic derivative compounds are potentially useful as non-estrogenic antioxidants, esp... | 08/20/2002 |
| 6417365 | Method for recovering medicaments from preparations, and from the precursors or wastes thereof In a process for recovering medicinal substances or active substances from preparations, their initial products or waste, a flat-shaped starting material in the form of a film with adhesive and an active substance-containing material is provided with one ... | 07/09/2002 |
| 6333317 | Regulation of amyloid precursor protein (APP) expression by administration of an estrogenic compound It has been discovered that lipophilic hormones that interact with cytosolic or nuclear receptors regulate APP expression and synthesis, through modification of APP mRNA stability and/or regulation of APP gene transcription and translation activities. The... | 12/25/2001 |
| 6271220 | Anti-angiogenic agents The application discloses methods of treating mammalian diseases characterized by undesirable angiogenesis by administering compounds including those having the general formulae ##STR1## wherein A is a fused tropone having a general formula: ##STR2##... | 08/07/2001 |
| 6201141 | Determination of steroids by competitive immunoassay A method and kit for measurement of a steroid by means of a competitive immunoassay, preferably a competitive enzyme immunoassay. The method and kit involve the use of a steroid analogue conjugated to a label. The steroids that are amenable to detection b... | 03/13/2001 |
| 6169082 | Salts of 8,9-dehydroestrone sulfate ester This invention presents alkali metal salts of 8,9-dehydroestrone, salts of its sulfate ester, and stable compositions thereof, as well as processes for their production and use in estrogen replacement therapy and cardiovascular protection.... | 01/02/2001 |
| 5998639 | Sulfatation of estrogen mixtures The invention relates to a method for the preparation of a mixture of sulfated estrogens containing delta(8,9)-dehydro estrone [delta(8,9)DHE] or derivatives thereof.... | 12/07/1999 |
| 5994568 | Estrenes for inducing hypothalamic effects The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.... | 11/30/1999 |
| 5986115 | 7-(.xi.-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7-(.xi.-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents This invention describes new, substituted 7-(.xi.-aminoalkyl)-estratrienes of general formula I ##STR1## in which side chain SK is a radical of partial formula ##STR2## as well as their physiologically compatible addition salts with organ... | 11/16/1999 |
| 5977096 | Steroids with radical-attracting aromatic substituents, process for the production thereof and pharmaceutical compounds containing the said substances Novel substituted steroid compounds are disclosed which are more effective than known radical-trapping agents in methods of prophylaxis and therapy of radical-mediated cell damage and of treatment of diseases due to radical-mediated cell damage. The novel... | 11/02/1999 |
| 5939570 | Estrenes for inducing hypothalamic effects The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.... | 08/17/1999 |
| 5928666 | Crystalline form of estradiol and pharmaceutical formulations comprising same The present invention is directed to a stable crystalline form of estradiol suitable for incorporation into pharmaceutical formulations. The invention further provides methods of preparing said crystalline form of estradiol. The invention further provides... | 07/27/1999 |
| 5892069 | Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found belo... | 04/06/1999 |
| 5840889 | Synthesis of estrogen-purine base and estrogen-mercapturate adducts and development of fluorescent probes and monoclonal antibodies to assay those adducts Estrogen-nucleoside, estrogen-guanine and estrogen-mercapturate adducts are potential biomarkers for determining susceptibility of animals to a number of estrogen related cancers. These adducts may be used as biomarkers for determining risk of estrogen-in... | 11/24/1998 |
| 5798348 | Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight The pharmaceutical and/or cosmetic compositions for treatment of obesity and/or overweight contain an effective amount of a fatty-acid monoester of an estrogen and a fatty acid wherein the estrogen is estrone, diethylstilbestrol, estriol, estradiol or eth... | 08/25/1998 |
| 5739363 | Isomerisation of equilin The invention relates to a method of isomerisation of equilin or a derivative thereof to delta(8,9)-dehydro estrone delta(8,9)DHE!, characterized in that equilin or a derivative thereof is treated with a lithium salt of ethylenediamine or with lithium a... | 04/14/1998 |
| 5633392 | Estrenes for inducing hypothalamic effects The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.... | 05/27/1997 |
| 5621124 | Process for the alkylation of estrone derivatives The invention relates to a process for the alkylation of estrone derivatives, which is characterized in that a suspension of the estrone derivatives in dimethylformamide is produced and carbonic acid diester and guanidine and/or alkyl guanidines are disso... | 04/15/1997 |
